As the ALS field progresses, marked by pivotal approvals and mounting investment into preclinical and clinical pipelines, the 3rd ALS Drug Development meeting returned as industry’s comprehensive guide to accelerate transformative treatments to patients faster. 

What Did You Miss?

Two dedicated tracks

Brand-New Speakers

Cutting-edge data readouts

Novel patient insight

Extended Regulatory Discussions

What You Missed:

Characterize expression of TDP-43 and C9orf72 among diverse forms of ALS. Look beyond TDP-43 to discover next-generation targets, with clinical updates on PIKfyve, STATHMIN-2, Tregs and more. 


Build translational confidence of a truly sporadic iPSC model, leverage co-cultures to study cellular interactions in ALS, and overcome aggressive in vivo phenotypes caused by TDP-43 overexpression. 


Modernize the clinical trial approach by incorporating DHTs, AI and digital biomarkers. Navigate hurdles of demonstrating efficacy on top of existing ALS therapies, while optimizing the potential of a combination approach.

2 (1)

Decipher the most meaningful endpoints to people living with ALS and evaluate the potential of novel surrogate biomarkers that extend beyond ALSFRS-R to monitor patients, enhancing dialogue with regulatory bodies about what these could be.

4 (1)

Explore novel biomarker opportunities to better understand ALS progression and detect sporadic ALS at the pre-symptomatic stage. Collaborate for earlier genetic testing to accelerate the onset of treatment for ALS gene carriers.


Hear From Last Year’s Attendees:

"Very relevant topics. Awesome and knowledgeable presenters. One of the best ALS meetings I have been to.”

Vice President Clinical Development, PTC Therapeutics 

“The quality and expertise of the speakers was exceptional and the unique mix of academic and industry speakers in a collaboration also made it very valuable.”

Senior Director, Medical, Argenx 

“This conference is an opportunity to learn about the latest in ALS drug development and network with peers.”

Head of Global Medical Affairs, Amylyx Pharmaceuticals